Clinical Trials of Immunogene Therapy for Spontaneous Tumors in Companion Animals
Despite the important progress obtained in the treatment of some pets’ malignancies, new treatments need to be developed. Being critical in cancer control and progression, the immune system’s appropriate modulation may provide effective therapeutic options. In this review we summarize the outcomes o...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1155/2014/718520 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832546162985402368 |
|---|---|
| author | Gerardo Claudio Glikin Liliana María Elena Finocchiaro |
| author_facet | Gerardo Claudio Glikin Liliana María Elena Finocchiaro |
| author_sort | Gerardo Claudio Glikin |
| collection | DOAJ |
| description | Despite the important progress obtained in the treatment of some pets’ malignancies, new treatments need to be developed. Being critical in cancer control and progression, the immune system’s appropriate modulation may provide effective therapeutic options. In this review we summarize the outcomes of published immunogene therapy veterinary clinical trials reported by many research centers. A variety of tumors such as canine melanoma, soft tissue sarcomas, osteosarcoma and lymphoma, feline fibrosarcoma, and equine melanoma were subjected to different treatment approaches. Both viral and mainly nonviral vectors were used to deliver gene products as cytokines, xenogeneic tumor associated antigens, specific ligands, and proapoptotic regulatory factors. In some cases autologous, allogenic, or xenogeneic transgenic cytokine producing cells were assayed. In general terms, minor or no adverse collateral effects appeared during this kind of therapies and treated patients usually displayed a better course of the disease (longer survival, delayed or suppressed recurrence or metastatic spread, and improvement of the quality of life). This suggests the utility of these methodologies as standard adjuvant treatments. The encouraging outcomes obtained in companion animals support their ready application in veterinary clinical oncology and serve as preclinical proof of concept and safety assay for future human gene therapy trials. |
| format | Article |
| id | doaj-art-d068023cace3469289e20cf4a7d15517 |
| institution | Kabale University |
| issn | 2356-6140 1537-744X |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-d068023cace3469289e20cf4a7d155172025-02-03T07:23:49ZengWileyThe Scientific World Journal2356-61401537-744X2014-01-01201410.1155/2014/718520718520Clinical Trials of Immunogene Therapy for Spontaneous Tumors in Companion AnimalsGerardo Claudio Glikin0Liliana María Elena Finocchiaro1Unidad de Transferencia Genética, Instituto de Oncología “Ángel H. Roffo”, Universidad de Buenos Aires, 1417 Buenos Aires, ArgentinaUnidad de Transferencia Genética, Instituto de Oncología “Ángel H. Roffo”, Universidad de Buenos Aires, 1417 Buenos Aires, ArgentinaDespite the important progress obtained in the treatment of some pets’ malignancies, new treatments need to be developed. Being critical in cancer control and progression, the immune system’s appropriate modulation may provide effective therapeutic options. In this review we summarize the outcomes of published immunogene therapy veterinary clinical trials reported by many research centers. A variety of tumors such as canine melanoma, soft tissue sarcomas, osteosarcoma and lymphoma, feline fibrosarcoma, and equine melanoma were subjected to different treatment approaches. Both viral and mainly nonviral vectors were used to deliver gene products as cytokines, xenogeneic tumor associated antigens, specific ligands, and proapoptotic regulatory factors. In some cases autologous, allogenic, or xenogeneic transgenic cytokine producing cells were assayed. In general terms, minor or no adverse collateral effects appeared during this kind of therapies and treated patients usually displayed a better course of the disease (longer survival, delayed or suppressed recurrence or metastatic spread, and improvement of the quality of life). This suggests the utility of these methodologies as standard adjuvant treatments. The encouraging outcomes obtained in companion animals support their ready application in veterinary clinical oncology and serve as preclinical proof of concept and safety assay for future human gene therapy trials.http://dx.doi.org/10.1155/2014/718520 |
| spellingShingle | Gerardo Claudio Glikin Liliana María Elena Finocchiaro Clinical Trials of Immunogene Therapy for Spontaneous Tumors in Companion Animals The Scientific World Journal |
| title | Clinical Trials of Immunogene Therapy for Spontaneous Tumors in Companion Animals |
| title_full | Clinical Trials of Immunogene Therapy for Spontaneous Tumors in Companion Animals |
| title_fullStr | Clinical Trials of Immunogene Therapy for Spontaneous Tumors in Companion Animals |
| title_full_unstemmed | Clinical Trials of Immunogene Therapy for Spontaneous Tumors in Companion Animals |
| title_short | Clinical Trials of Immunogene Therapy for Spontaneous Tumors in Companion Animals |
| title_sort | clinical trials of immunogene therapy for spontaneous tumors in companion animals |
| url | http://dx.doi.org/10.1155/2014/718520 |
| work_keys_str_mv | AT gerardoclaudioglikin clinicaltrialsofimmunogenetherapyforspontaneoustumorsincompanionanimals AT lilianamariaelenafinocchiaro clinicaltrialsofimmunogenetherapyforspontaneoustumorsincompanionanimals |